January 1, 2011 -- Kangmei Pharma will raise up to $529 million through a rights offering; Sichuan Kelun Pharma will purchase Guangdong Qingfa Pharma for $22.3 million; Beijing Double-Crane will acquire antibiotic maker Enshi Pharma for $13.7 million; Chindex and Fosun Pharma have formally created their previously announced medical device JV; Emerging Healthcare Solutions in-licensed China rights to a stem cell culturing technology; and Sinovac received SFDA approval to begin clinical trials of an EV71 vaccine, as did China National Biotech Group for its EV71 vaccine. More details….
